Lucid Capital initiated coverage of MeiraGTx (MGTX) with a Buy rating and $50 price target MeiraGTx is developing next-generation, genetic medicines to potentially unlock cures in chronic diseases, the analyst tells investors in a research note. The firm says the company is “providing a toolbox to pharma.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX: